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Introduction {#jdv14691-sec-0006}
============

Prevalence rates of actinic keratosis (AK) in Europe are increasing with the ageing population. A multicenter study across eight European countries confirmed the importance of chronic and high intermittent UV exposure, fair skin type and red or blonde hair as important risk factors for AK.[1](#jdv14691-bib-0001){ref-type="ref"}

Although not all AKs will progress to invasive squamous cell carcinoma (SCC) and some may regress, guidelines recommend treating AK as they are recognized as precursors of invasive SCC.[2](#jdv14691-bib-0002){ref-type="ref"}

Photodynamic therapy (PDT) is recommended as a first‐line treatment for individual (lesion‐directed therapy) or multiple and/or confluent AKs (field therapy) and has the potential to delay/reduce the development of new lesions.[2](#jdv14691-bib-0002){ref-type="ref"}, [3](#jdv14691-bib-0003){ref-type="ref"}, [4](#jdv14691-bib-0004){ref-type="ref"} Methyl aminolevulinate (MAL) cream with red light (conventional PDT; c‐PDT) is indicated for the treatment of thin or non‐hyperkeratotic and non‐pigmented AKs on the face and scalp, superficial and/or nodular basal cell carcinoma and SCC *in situ* (Bowen\'s disease). More recently, MAL with daylight (MAL DL‐PDT) has shown good efficacy and safety in the treatment of face and scalp, mild‐to‐moderate AK in multiple studies and has been approved in many countries for this indication.[5](#jdv14691-bib-0005){ref-type="ref"}, [6](#jdv14691-bib-0006){ref-type="ref"} In a randomized, controlled trial in Europe, MAL DL‐PDT demonstrated similar efficacy, better tolerability with less pain and resulted in higher subject satisfaction compared to MAL c‐PDT.[6](#jdv14691-bib-0006){ref-type="ref"} Furthermore, a structured expert consensus statement on AK recently rated MAL DL‐PDT as the preferred option for patients with multiple AKs on both small and large fields due to its efficacy and tolerability profile.[7](#jdv14691-bib-0007){ref-type="ref"}

The objective of this study was to generate real‐world data on patient and physician satisfaction, as well as efficacy and safety, of MAL DL‐PDT in the treatment of face and scalp, mild‐to‐moderate AK in Europe.

Methods {#jdv14691-sec-0007}
=======

Study design {#jdv14691-sec-0008}
------------

A prospective, multicenter, non‐interventional study was conducted in six European countries (Italy, Spain, France, the Netherlands, Switzerland and the United Kingdom) at a total of 52 sites. Eligible patients were aged 18 years or older and had been prescribed MAL DL‐PDT as part of their routine medical care to treat mild‐to‐moderate AK on the face and/or scalp.

The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization‐Good Clinical Practice principles and in compliance with local regulatory requirements. The study was reviewed and approved by the appropriate Independent Ethics Committees, and written informed consent was obtained from all patients prior to study initiation. The study is registered at ClinicalTrials.gov identifier NCT02674048.

Treatment {#jdv14691-sec-0009}
---------

A single treatment of MAL DL‐PDT was administered (Metvix^®^/Metvixia^®^, Galderma, Laboratories, Paris, France) according to the local Summary of Product Characteristics.

Assessments {#jdv14691-sec-0010}
-----------

At baseline, the number and global severity of AK lesions were assessed by the physician and a follow‐up visit for reassessment was proposed at 3 months. Efficacy was assessed using a 6‐point global improvement scale from 1 (clear) to 6 (worse). Patient‐reported outcomes were assessed by patient questionnaires at baseline and at 3 months. Each physician completed a questionnaire when all their study patients had completed the study. Post‐treatment pain was assessed after treatment administration on a numerical rating scale (NRS) from 0 (no pain) to 10 (extreme pain). Incidence and severity of adverse events (AE) were recorded at each study visit.

Statistical methods {#jdv14691-sec-0011}
-------------------

All collected variables were descriptively summarized without replacement of any missing values (observed data only).

Results {#jdv14691-sec-0012}
=======

Study population {#jdv14691-sec-0013}
----------------

Between April 2016 and August 2016, 325 patients were enrolled, including 69 from Italy, 57 from Spain, 56 from France, 55 from the Netherlands and 44 from each of Switzerland and the United Kingdom. Overall, 314 (96.6%) attended a follow‐up visit 3 months after treatment.

Most patients were elderly (mean age 74.1 years) men (84.0%), and the majority had skin phototype II (68.0%) (Table [1](#jdv14691-tbl-0001){ref-type="table"}). Among the patients who had received previous treatment for AK (88.9%), the mean duration of past AK treatments was 7.2 years and 36.0% and 14.5% of patients had previously received c‐PDT and DL‐PDT, respectively.

###### 

Baseline demographic and clinical characteristics of the study population

                                                                                                       Patients, *n* (%) *N* = 325
  -------------------------------------------------------------- ------------------------------------- -----------------------------
  **Age (years)**                                                Mean ± SD                             74.1 ± 9.0
                                                                 Min‐max                               41--95
  **Gender**                                                     Male                                  273 (84.0%)
  **Skin phototype**                                             Type I                                38 (11.7%)
                                                                 Type II                               221 (68.0%)
                                                                 Type III                              64 (19.7%)
                                                                 Type IV                               2 (0.6%)
  **Previous AK treatment received**                             Yes                                   289 (88.9%)
                                                                 Cryotherapy                           233 (80.6%)
                                                                 Conventional PDT                      104 (36.0%)
                                                                 Fluorouracil                          61 (21.1%)
                                                                 Diclofenac                            56 (19.4%)
                                                                 Ingenol mebutate                      49 (17.0%)
                                                                 Surgery                               46 (15.9%)
                                                                 Daylight PDT                          42 (14.5%)
                                                                 Imiquimod                             37 (12.8%)
                                                                 Laser                                 10 (3.5%)
                                                                 Peelings                              4 (1.4%)
                                                                 Other                                 7 (2.4%)
  **Past medical history of AK treatments (years), *N* = 289**   Mean ± SD                             7.2 ± 5.9
                                                                 Median (min‐max)                      5.0 (0--35)
  **Number of lesions**                                          \<5                                   29 (8.9%)
                                                                 5--10                                 106 (32.6%)
                                                                 11--20                                108 (33.2%)
                                                                 \>20                                  82 (25.2%)
  **Location of lesions**                                        Scalp                                 195 (60.0%)
                                                                 Forehead                              176 (54.2%)
                                                                 Cheek                                 103 (31.7%)
                                                                 Nose                                  84 (25.8%)
                                                                 Full face                             54 (16.6%)
  **Global severity of the lesions**                             Majority of grade I                   128 (39.4%)
                                                                 Majority of grade II                  108 (33.2%)
                                                                 Well‐balanced mix of grade I and II   89 (27.4%)
  **Grade III lesions present**                                  Yes                                   34 (10.5%)

PDT, photodynamic therapy.

John Wiley & Sons, Ltd

The majority of patients had multiple lesions (58.4% had \>10 lesions) with most lesions located on the scalp (60.0%) and/or forehead (54.2%) (Table [1](#jdv14691-tbl-0001){ref-type="table"}). Patients had lesions of predominantly grade I (39.4%), grade II (33.2%) or a mix of grade I and II (27.4%), and 10.5% of patients also had grade III AK (Table [1](#jdv14691-tbl-0001){ref-type="table"}).

All physicians (*N* = 52) were experienced dermatologists with a mean of 20.4 years (min‐max 9--33) in clinical practice, and they treated 26 AK patients per week on average (min‐max 30--100). The main reasons given by the physicians for choosing MAL DL‐PDT were the high number and location of lesions over a large area to be treated, treatment tolerability and efficacy and patient adherence (see Table [2](#jdv14691-tbl-0002){ref-type="table"}).

###### 

Daylight‐activated methyl aminolevulinate treatment procedure

                                                                            Patients, *n* (%) *N* = 325
  ------------------------------------------------------------------------- -----------------------------
  **Major consideration when choosing MAL DL‐PDT treatment**                
  Large area to treat                                                       286 (88.0%)
  High number of AK lesions                                                 262 (80.6%)
  Tolerability                                                              260 (80.0%)
  Location of lesions                                                       244 (75.1%)
  Efficacy                                                                  236 (72.6%)
  Maintenance of AK clearance                                               185 (56.9%)
  Patient adherence                                                         172 (52.9%)
  Cosmetic benefits                                                         100 (30.8%)
  Cost                                                                      26 (8.0%)
  **Preparation of skin before MAL application**                            282 (86.8%)
  On entire field                                                           153 (54.3%)
  Lesions only                                                              129 (45.7%)
  **Method, *N* = 282**                                                     
  Curette                                                                   201 (71.3%)
  Skin abrasive pad                                                         51 (18.1%)
  Keratolytic cream for a few days before                                   46 (16.3%)
  Microdermabrasion                                                         3 (1.1)
  Other                                                                     6 (2.1%)
  **Sunscreen applied**                                                     270 (83.1%)
  Before skin preparation and before MAL                                    196 (72.6%)
  After skin preparation but before MAL                                     74 (27.4%)
  **Location of MAL application**                                           
  On entire field                                                           261 (80.3%)
  On lesions only                                                           64 (19.7%)
  **Time between MAL application and daylight exposure (min), *N* = 168**   
  Mean ± SD                                                                 14.6 ± 11
  Median (min‐max)                                                          10 (0--60)
  **Time of daylight exposure (h), *N* = 168**                              
  Mean ± SD                                                                 2.0 ± 0.1
  Median (min‐max)                                                          2.0 (1.5--3.0)
  **Total time of MAL exposure (h), *N* = 168**                             
  Mean ± SD                                                                 2.4 ± 0.3
  Median (min‐max)                                                          2.3 (2--4.5)
  **Post‐treatment care recommended**                                       320 (98.5%)
  Sunscreen                                                                 296 (92.5%)
  Moisturizer                                                               198 (61.9%)
  Cleanser                                                                  164 (51.3%)

MAL DL‐PDT, Daylight‐activated methyl aminolevulinate.

John Wiley & Sons, Ltd

MAL DL‐PDT procedure {#jdv14691-sec-0014}
--------------------

Before MAL application, the skin was prepared in most patients (86.8%) and curettage (71.3%) was the most frequently used method (Table [2](#jdv14691-tbl-0002){ref-type="table"}). The entire field was prepared in around half the patients (54.3%) and the lesions only in around half (45.7%). The majority of patients applied sunscreen (83.1%), mostly before skin preparation (72.6%).

MAL was applied on the entire field for most patients (80.3%). After MAL application, patients went outside on average 14.6 min later and stayed outside in the daylight for 2.0 h (Table [2](#jdv14691-tbl-0002){ref-type="table"}).

Post‐treatment care was recommended to the vast majority of patients (98.5%), especially sunscreen application (92.5%) (Table [2](#jdv14691-tbl-0002){ref-type="table"}).

Efficacy {#jdv14691-sec-0015}
--------

In this patient population with multiple lesions, physician‐assessed efficacy at 3 months was at least much improved in 83.5% of patients with 45.9% of patients requiring no retreatment at month 3. Of the patients (54.1%) requiring further treatment at 3 months for residual lesions, the preferred treatments were cryotherapy (55.3%) or MAL DL‐PDT (21.2%).

Patient and physician satisfaction {#jdv14691-sec-0016}
----------------------------------

At baseline after the MAL DL‐PDT procedure, the vast majority of subjects (94.0%) indicated that the procedure was convenient to very convenient (Fig. [1](#jdv14691-fig-0001){ref-type="fig"}).

![Convenience of the daylight‐activated methyl aminolevulinate treatment, as expressed by patients after treatment.](JDV-32-757-g001){#jdv14691-fig-0001}

At end of study, the proportion of patients and physicians overall satisfied to very satisfied with the MAL DL‐PDT treatment was 80.4% and 90.3%, respectively. Most patients and physicians were satisfied or very satisfied with the effectiveness of the MAL DL‐PDT treatment (78.9% and 82.6%, respectively) and with the cosmetic appearance of the treated skin (76.9% and 98.1%, respectively) (Fig. [2](#jdv14691-fig-0002){ref-type="fig"}a).

![According to patient and physician questionnaires at end of study (a) satisfaction with the treatment effectiveness and the cosmetic appearance of the treated skin and (b) proportion who would use daylight‐activated methyl aminolevulinate again.](JDV-32-757-g002){#jdv14691-fig-0002}

The vast majority of patients (90.0%) and physicians (98.1%) would consider using MAL DL‐PDT again (Fig. [2](#jdv14691-fig-0002){ref-type="fig"}b).

Safety {#jdv14691-sec-0017}
------

After receiving the treatment, 66.2% of patients indicated they were not bothered at all by pain (Fig. [3](#jdv14691-fig-0003){ref-type="fig"}) and the mean pain level was 1.4 (0--10 NRS scale).

![Patients\' responses to the questions 'How bothered by any pain?' (questionnaire after treatment) and 'How bothered by side‐effects?' (questionnaire at end of study).](JDV-32-757-g003){#jdv14691-fig-0003}

Related AEs were reported in 14.8% of patients, but most were mild in severity (10.8%).

The most commonly reported AEs were phototoxic AEs including skin irritation (4.6%), skin burning sensation (3.7%) and erythema (3.4%) (Table [3](#jdv14691-tbl-0003){ref-type="table"}).

###### 

Overall related adverse events during the treatment visit and during the 3‐month follow‐up

                                               Events   Patients, *n* (%) *N* = 325
  -------------------------------------------- -------- -----------------------------
  **Related adverse events**                   66       48 (14.8%)
  **Skin and subcutaneous tissue disorders**   66       48 (14.8%)
  Skin irritation                              15       15 (4.6%)
  Skin burning sensation                       12       12 (3.7%)
  Erythema                                     11       11 (3.4%)
  Scab                                         10       10 (3.1%)
  Pruritus                                     9        9 (2.8%)
  Pain of skin                                 4        4 (1.2%)
  Skin exfoliation                             4        4 (1.2%)
  Dermatitis                                   1        1 (0.3%)

John Wiley & Sons, Ltd

At the 3‐month visit, 62.2% of patients indicated they were not bothered at all by side‐effects (Fig. [3](#jdv14691-fig-0003){ref-type="fig"}) and the mean duration of downtime due to skin reactions was 3.4 ± 7.1 days. The vast majority of physicians (86.5%) indicated they were very satisfied with the tolerability of MAL DL‐PDT (Fig. [4](#jdv14691-fig-0004){ref-type="fig"}).

![Physician satisfaction with the tolerability of daylight‐activated methyl aminolevulinate treatment.](JDV-32-757-g004){#jdv14691-fig-0004}

Discussion {#jdv14691-sec-0018}
==========

In this population of patients, most of whom were naïve to MAL DL‐PDT (85.5%), high patient satisfaction (80.4% overall satisfied/very satisfied) was observed with this convenient (94.0% found it to be convenient/very convenient), almost painless procedure. Furthermore, despite the large number of lesions and large areas treated, 83.5% of patients were at least much improved at 3 months after a single treatment with MAL DL‐PDT, which may also have contributed to the high patient satisfaction. The overall patient satisfaction was similar to the levels reported in a randomized controlled Phase III study conducted in Europe (96.2% satisfied to very satisfied).[6](#jdv14691-bib-0006){ref-type="ref"}

The main reasons for prescribing MAL DL‐PDT in these patients were the large areas to be treated with many lesions, as well as its good tolerability and efficacy. As the surrounding area of sun‐damaged skin (field cancerization) next to visible or palpable AK lesions may contain subclinical lesions and cellular changes, treatment of the entire field is important to treat both subclinical lesions and visible AKs.[8](#jdv14691-bib-0008){ref-type="ref"}, [9](#jdv14691-bib-0009){ref-type="ref"} In this study, MAL DL‐PDT was applied to the entire field in 80.3% of patients. Of those patients (54.1%) requiring further treatment at 3 months for residual lesions, the main treatments considered were cryotherapy for residual individual lesions (55.3%) and around one‐fifth of patients (21.2%) received further treatment with MAL DL‐PDT.

Protocols for topical PDT conventionally recommend skin preparation to remove scales and crusts in order to enhance photosensitizing agent absorption and light penetration.[2](#jdv14691-bib-0002){ref-type="ref"} Skin preparation was performed over the entire field in half of the cases (54.3% of patients), with curettage of individual lesions (71.3%) much more commonly used than field skin preparations, such as skin abrasive pad or keratolytics (18.1% and 16.3%, respectively). More than one method could be used with, for example, curettage of individual lesions combined with a field skin preparation method.

Only 14.8% of patients had related AEs in this study, which is much lower than the 45.4% reported in the randomized controlled study conducted in Europe.[6](#jdv14691-bib-0006){ref-type="ref"} The results presented here for six European countries were part of a larger study, which also included 81 Australian patients. In the Australian study, almost half of the patients (48.1%) experienced related AEs, mainly mild erythema.[10](#jdv14691-bib-0010){ref-type="ref"} Phototoxic events are expected and appear to have been under‐reported in this European observational study, possibly due to the fact that they were mild in severity and there was no visit at week 1. Indeed, mild phototoxic events are not necessarily considered as adverse events as photosensitivity from PDT is a desirable, intrinsic reaction due to the treated area being sensitized to light. By the 3‐month visit, almost two‐thirds (62%) of patients indicated they had not been bothered at all by side‐effects and the average downtime of 3.4 days was considered acceptable.

Factors that may have contributed to the high patient and physician satisfaction with MAL DL‐PDT include the convenient single treatment session (compared to several days for ingenol mebutate to weeks for imiquimod and 5‐fluorouracil, even months with diclofenac plus hyaluronic acid gel).

A randomized, split‐face, clinical trial on small areas of 25 cm^2^ harbouring a similar number of AKs, comparing a single session of MAL DL‐PDT with a 3‐day treatment with ingenol mebutate, demonstrated similar efficacy for both treatments on face and scalp AKs.[11](#jdv14691-bib-0011){ref-type="ref"} However, MAL DL‐PDT was associated with lower pain and inflammation scores, quicker wound healing, better cosmetic outcome and higher patient preference (77% preferred MAL DL‐PDT vs. 33% for ingenol mebutate).[11](#jdv14691-bib-0011){ref-type="ref"} Similarly, in an intraindividual comparative analysis, MAL DL‐PDT showed similar effectiveness with a superior tolerability profile in terms of local skin responses and pain compared to ingenol mebutate.[12](#jdv14691-bib-0012){ref-type="ref"} In an indirect comparison study in the treatment of mild‐to‐moderate AK, MAL DL‐PDT was more than four times more effective than diclofenac plus hyaluronic acid gel at 12 weeks.[13](#jdv14691-bib-0013){ref-type="ref"}

Limitations of this study are the non‐interventional nature and lack of a control group. However, this observational study on a large sample size of patients (*n* = 325) and investigators (*n* = 52) provided real‐world evidence to support the results of a previous randomized controlled trial conducted in Europe.[6](#jdv14691-bib-0006){ref-type="ref"}

Conclusions {#jdv14691-sec-0019}
===========

Findings of this observational study in Europe are consistent with those from previous trials and demonstrate high levels of patient and physician satisfaction with MAL DL‐PDT, reflecting the good efficacy and high tolerability of this convenient procedure in treating multiple mild‐to‐moderate AK of the face and/or the scalp.
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